0.50 / AMA PRA Category 1 CreditTM 0.50 / CE for Pharmacists (0.05 CEUs)
CME: Albert Einstein College of Medicine ACPE: University of Wisconsin-Madison Division of Pharmacy Professional Development
Supported by an educational grant from Janssen Therapeutics
Produced by Haymarket Medical Education
Current guidelines from the US Department of Health and Human Services (DHHS) support the early initiation of antiretroviral therapy (ART) in all patients who test positive for HIV. Over the past decade, huge strides have been made in HIV treatment. Improvements in ART continue with the development of simplified, single-tablet treatments and more effective regimens. While newer agents can improve tolerability and adherence, leading to less viral resistance, certain older agents are no longer recommended, generally due to suboptimal efficacy or toxicity profiles. Reflecting these advances, the DHHS guidelines now recommend more targeted treatment options, with many of the suggested regimens incorporating recently approved drugs.
HIV treatment is life-long and is often very costly. It is estimated that, over the course of a patient’s life, drug costs may be more $500K. Currently, HIV therapies are a top category of specialty drug spending and, even with health care insurance, these medications can be unaffordable for many patients. In this activity, W. David Hardy, MD and Joseph Eron, MD, discuss the current DHHS recommendations and the need to individualize treatment according to the needs and characteristics of each patient. Cost considerations and strategies by which clinicians can ensure patients have early and sustained access to HIV therapies will be discussed.
Managed care medical and pharmacy directors (primary audience); primary care clinicians (secondary audience); and all physicians and pharmacists
At the conclusion of this activity, participants should be better able to:
Assess current guidelines and interpret new clinical data to optimize the selection of treatment regimens for patients with HIV
Evaluate HIV switching strategies that may benefit patients with virologic suppression
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, the University of Wisconsin-Madison, the Albert Einstein College of Medicine, and Haymarket Medical Education (HME) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Course Director Barry S. Zingman, MD Medical Director, AIDS Center Clinical Director, Infectious Diseases, Moses Division Montefiore Medical Center Professor of Clinical Medicine, Albert Einstein College of Medicine Bronx, NY
Dr. Zingman has nothing to disclose with regard to financial interests.
Course Reviewer Victor B. Hatcher, PhD Research Director Montefiore Medical Center Associate Dean Professor of Biochemistry and Medicine Albert Einstein College of Medicine Bronx, NY
Dr. Hatcher has nothing to disclose with regard to financial interests.
Joseph Eron, MD Professor of Medicine University of North Carolina at Chapel Hill School of Medicine Chapel Hill, NC
Dr. Eron is a consultant for Bristol-Meyers Squibb, Gilead, Merck, Roche Molecular Systems, Tibotec/Janssen and ViiV Healthcare. He also receives research grants to the University of North Carolina from AbbVie, Bristol-Meyers Squibb, Gilead Sciences, Janssen, and ViiV Healthcare.
W. David Hardy, MD, AAHIVS Senior Director, Evidence-based Practices Whitman-Walker Health Washington, DC Division of Infectious Diseases Adjunct Professor of Medicine Johns Hopkins University School of Medicine Baltimore, MD
Dr. Hardy is a consultant for Gilead, Janssen, ViiV Healthcare/GSK, and Theratechnologies. He also does contracted research for Amgen, Bristol-Meyers Squibb, Gilead, Janssen, Merck, and ViiV Healthcare/GSK.
Accredited Provider Disclosure
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine has nothing to disclose with regard to commercial support.
The staff of the University of Wisconsin-Madison Interprofessional Continuing Education Partnership (ICEP) has nothing to disclose with regard to commercial support.
Publishing Staff Disclosures
Krista Sierra and Susan Basilico of Haymarket Medical Education have nothing to disclose with regard to commercial support.
AMA PRA Category 1 Credit(s)TM
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Albert Einstein College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM . Physicians should only claim those credits commensurate with the extent of their participation in the activity.
CE for Pharmacists
In support of improving patient care, the University of Wisconsin-Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
A total of 0.50 hours (0.05 CEUs) of pharmacy CE credit will be provided for successful completion of this knowledge-based program. To receive CE credit, you must complete the program; complete the evaluation; and complete the post-test with a minimum score of 70%. Verification of completion will be provided to NABP within 2 days of completion of this program. No credit will be provided 60 days after this program expires.
Universal Program #0073-9999-17-046-H02-P
Disclosure of Unlabeled Use
This CME activity will not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine, University of Wisconsin-Madison, Janssen Therapeutics, and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 70% or better on the post-test is required. Please proceed until you have successfully completed this activity and completed the post-test and evaluation, and for CME credit only, that you have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For CPE credit, your credit will automatically be provided to NABP. Please verify that your credit has been recorded by checking your NABP profile after 2 business days.